

Pfizer is proud to announce the 2011 cycle of grant awards for scientific research of the highest quality in the field of anti-infectives

Pfizer Anti-Infectives Research Foundation

A competitive grant programme organised and funded by Pfizer and led by an independent scientific advisory committee

Accepting applications from Wednesday 1 December 2010

Closing date for applications: 31 March 2011



Advancing science through the Pfizer Anti-Infectives Research Foundation

The *Pfizer Anti-Infectives Research Foundation* is looking to fund innovative research projects in the field of bacterial and fungal infections.

A total of £200,000 is available to support appropriate research initiatives during 2011.

- It is anticipated that awards of approximately £50,000 will be made, the awards could be greater based on the research proposal submitted.
- In exceptional circumstances, the maximum award limit for a single grant application is £100,000.
- The non-renewable grant will be for research to be undertaken within a single calendar year.
- Overhead costs cannot be included within *Pfizer Anti-Infectives Research Foundation* grant applications.

Submissions will be evaluated once a year and selected areas of research will vary annually.

Aims

The Foundation aims to inspire high-quality and innovative anti-infectives research which may result in excellence in patient care.

Eligibility criteria

Applications for funding are open to all clinical practitioners and scientists working in the UK who do not work for Pfizer and hold medical or pharmacy degrees or PhDs.

The applications should focus on translational (clinically-orientated) research that will impact patient outcomes. Applications regarding research in the late-laboratory phase will also be considered.

For 2011, applications in the following areas will be considered:

- clinical diagnostics for invasive aspergillosis
- epidemiology of serious fungal infections (*Aspergillus* and *Candida*) in the UK
- innovative approaches to the management of surgical-related infections, which are linked to hospital-acquired infections
- antibiotic stewardship programmes looking at cost, outcomes and resistance in serious gram-positive and gram-negative infections.

In exceptional circumstances, applications outside of the stated criteria, such as proposals of high scientific merit that will advance current clinical knowledge in the field of anti-infectives, may also be considered.

Scientific Advisory Committee

The Foundation is led by an independent multidisciplinary panel of leading UK medical experts with a specialist interest in the areas of bacterial and/or fungal infections. The panel includes experts from the fields of microbiology, onco-haematology, intensive care, orthopaedic surgery and vascular surgery who form the Scientific Advisory Committee (SAC). This committee is supported by the medical team lead from Pfizer UK anti-infectives.

The independent panel of leading UK medical experts will review all research proposals, determine the successful applicants and make awards to recipients. The committee will be chaired by Professor Homer-Vanniasinkam.

SAC Chair

Professor Shervanthi Homer-Vanniasinkam
BSc, MD, FRCS (Ed), FRCS

Professor Homer-Vanniasinkam is Consultant Vascular Surgeon at The General Infirmary at Leeds and Clinical Sub-Dean of Leeds Medical School. She holds a Personal Chair in Clinical and Experimental Vascular Research and is Chair of Translational Vascular Medicine at the University of Bradford. She is Director of Research and Education at Northwick Park Institute for Medical Research (affiliated to University College London), and Honorary Professor in the Division of Surgical and Interventional Sciences at University College London. In 2006, she successfully launched a novel undergraduate medical research scholarship programme, Leeds Undergraduate Research Enterprise (LURE). She holds several Visiting Professorships and has authored more than 90 papers.

SAC members

Professor Chris Kibbler MA, FRCP, FRCPath

Professor Kibbler is Clinical Lead Consultant Microbiologist at the Royal Free Hospital, London. He is Chair of the UK Clinical Mycology Network Steering Committee and President of the British Society for Medical Mycology.

Dr Brian L Jones BSc, MBChB, FRCPath

Dr Jones is a Consultant Clinical Microbiologist and Honorary Senior Clinical Lecturer at the University of Glasgow. He is the lead microbiologist for antimicrobial management in the Greater Glasgow and Clyde Health Board; Medical Director of the Scottish Parasite Diagnostic Laboratory; Deputy Director of the Scottish Haemophilus, Legionella, Meningococcus and Pneumococcus Reference Laboratory; and is a member of the Infection Groups of the European Organisation for Research and Treatment of Cancer, and the European Group for Blood and Marrow Transplantation.

Dr Antonio Pagliuca MBBS, MA, FRCP, FRCPath

Dr Pagliuca is Consultant Haematologist, Clinical/Transplant Director of Haematology, and Honorary Senior Lecturer at King's College Hospital, London. He is the immediate past-president of the British Society of Blood and Marrow Transplantation and a Trustee of Leukaemia Care. He sits on the Royal College of Physicians/ Royal College of Pathologists intercollegiate committee for haematology and the National Cancer Research Network's haematological malignancies working party. His department at King's College Hospital has the largest adult transplant programme in the UK, and has recently been designated as a Centre of Excellence by Leukaemia and Lymphoma Research.

Dr Katy Rezvani MBBS, PhD, MRCP, FRCPath

Dr Rezvani is Clinical Senior Lecturer at the Division of Investigative Science and a Consultant Haematologist at Imperial College London. She is Clinical Lead in allogeneic stem cell transplantation and Clinical Director of the Joint Accreditation Committee of the International Society for Cellular Therapy and The European Group for Blood and Marrow Transplantation-accredited good manufacturing practice cellular facility. She has an active research laboratory programme in transplant immunology and immunotherapy.

Mr Fares Haddad BSc, MCh (Orth), FRCS (Orth), FRCS (Ed), Dip. Sports Med, FFSEM

Mr Haddad is Consultant Orthopaedic Surgeon at University College London Hospitals, the Princess Grace Hospital and the Wellington Hospital in London. He is Divisional Clinical Director of Surgical Specialties at University College Hospital and Director of the Institute of Sport, Exercise and Health at University College London. His clinical and research interests are knee and hip pathology, reconstructive surgery and outcomes assessment.

Dr John Porter BA (Hons), MBBS, PhD, MRCPCH

Dr Porter joined Pfizer from the NHS in 2008, and was appointed medical team leader for Pfizer anti-infectives and vaccines in 2010. Dr Porter's PhD was in the genetics of childhood diabetes and he trained in Oxford and Newcastle medical schools. He then specialised in paediatric diabetes and endocrinology at Birmingham Children's Hospital. He continues to practice clinical medicine with weekly clinics in paediatrics.

How to apply

Please submit your application online through Pfizer's global Investigator-Initiated Research (IIR) website at **http://iirsubmission.pfizer.com**. If this is your first visit to the submission portal you must first 'Create an Account'. From the Home Page click on 'Create New Proposal' from the New Submission section. Read and agree to the policy on confidentiality and financial disclosure, then select the 'IIR (Investigator-Initiated Research) Program' to initiate your application. Select 'Yes' to the question 'Are you responding to a Competitive Grant Program' then choose 'AIR Foundation 2011' from the list of active programmes.

AIR Foundation 2011 Submissions

All submissions must be accompanied by the following documents:

- cover letter and research profile on applicant's institution letterhead
- an abbreviated curriculum vitae (maximum two pages of A4, minimum font size Arial 11 pt)
- research proposal abstract
- the three most relevant articles from the applicant's scientific publications (if applicable)
- description of available laboratory facilities
- listing of other research support available with a description of overlap and, if applicable, a listing of consenting collaborators (including an abbreviated curriculum vitae [maximum two pages of A4, minimum font size Arial 11 pt])
- budget information (detailed costs for conducting the proposed research)
- bibliography of relevant references
- final research proposal.

Research proposal abstract

In the online application portal, use the Study Synopsis field to provide an abstract of no more than 250 words for your proposed research. Applications with proposals over this word limit will **not** be accepted or reviewed by the SAC.

Research proposal

The research proposal should be attached and is limited to 5000 words or up to eight pages of single-spaced text (not including references, tables or details about research facilities). Applications with proposals over this word limit will **not** be accepted or reviewed by the SAC.

For questions and technical support relating to the online application process, please email **IIR@pfizer.com** or call the IIR hotline on (+1) 203 316 9059.

Overview of the 2011 grant allocation process

How will I know if I have been successful?

Letters informing applicants of the result of their applications will be sent in mid July 2011. Grants will be awarded in August 2011.

What project deliverables are required?

Research projects are expected to yield results that will advance knowledge in the field of anti-infectives. Awardees are expected to present findings at scientific meetings and/or publish them in scientific journals.

For further enquiries

For questions relating to the *Pfizer Anti-Infectives Research Foundation* award programme, please email **Air.Foundation@Pfizer.com**

ADVANCING **SCIENCE** • IMPROVING **LIVES**

Preparation date: December 2010

AIR-F 005